Dr. Paul F. Pilch

Degrees
B.A. Temple University
Ph.D. Purdue University, USA
Current position
Professor of Biochemistry & Department of Medicine, Boston University School of Medicine

Appointments
American Diabetes Association Grant Review Panel, member
NIH Cell Biology 2 Study Section, member
American Diabetes Association, Scientific Planning Committee, member & Chairman
Obesity Research, Associate Editor
Biochemical Journal, Academic Editor
Journal of Biological Chemistry, Editorial Board member
Associate Director, Graduate Program in Molecular Medicine, Boston University School of Medicine
Scientific Advisory Bard member, AdipoGenix

Consulting experience
Lilly
Merck
Millenium
Monsanto
Novartis
Novo Nordisk
Pfizer
Parke-Davis
Pharmacia/Upjohn
Searle.
Founder of AdipoGenix

Biography
Dr Pilch has established a strong reputation as one of the leading diabetes researchers worldwide. His research now focuses on obesity, a consequence of which is a dramatic rise in the incidence of type 2 diabetes mellitus. He studies aspects of insulin signaling and action, in particular characterizing the formation and protein content of GLUT4-containing vesicles and the physiological role of cell surface (plasma membrane) micro-domains called caveolae that are particularly abundant in these tissues. He provided evidence for the hypothesis that caveolae (for little caves that are small invaginations of the plasma membrane into the cytosol) are involved in lipid trafficking. Dr Pilch continues to study other aspects of adipocyte and muscle cell biology to understand the interplay between glucose and fat metabolism as well as the interplay between adipocytes and muscle required for overall metabolic homeostasis. He has an extensive track record in consulting, including with Lilly, Merck, Millenium, Monsanto, Novartis, Novo Nordisk, Pfizer, Parke-Davis, Pharmacia/Upjohn and Searle. He was a founder and now SAB member of AdipoGenix, a company with a focus on obesity drugs. For AdipoGenix he brokered a sucessful multi million dollar deal with Takeda.